Taken together, while AREG’s role in ovarian pathogenesis and chemoresistance has been established, AREG’s specific effects in the context of the ovarian TIME need to be elucidated, as unraveling its role in HGSOC tumor immunity could lead to novel therapeutic insights. This evidence concerns the gene AREG and neoplasm.